Partnering for Future Innovations and Access to Groundbreaking Therapies

We have a long history of collaborative and supportive partnerships with top academic institutions and companies.

Capricor has added experienced commercial company leadership with direct rare disease and Duchenne expertise, and continues to advance commercial readiness for a responsible and timely launch of Deramiocel ahead of its FDA PDUFA target action date of August 22, 2026. Preparations span manufacturing scale-up at our GMP facility, distribution strategy, market access, and reimbursement planning designed to support broad patient access across all payer segments.

Partnering for Future Innovations

Supportive collaborations include:

National Institutes of Health

• National Institute of Allergy and Infectious Diseases (NIAID)
• Division of Microbiology and Infectious Diseases (DMID)

U.S. Department of Defense

United States Army Institute of Surgical Research (USAISR)

University of Rome

Cedars-Sinai Medical Center

Johns Hopkins University

California Institute for Regenerative Medicine (CIRM)

Partner with Us

We are actively exploring partnership opportunities to maximize the full potential of our platform and pipeline. To inquire about partnering opportunities: Contact Us